Blog
RSS FeedPosted by Michael Wonder on 11 Dec 2020
Alunbrig scores NICE backing for ALK positive lung cancer
11 December 2020 - Takeda’s Alunbrig (brigatinib) has been recommended by the UK’s NICE for patients with ALK positive advanced ...
Posted by Michael Wonder on 08 Dec 2020
NICE backs AstraZeneca's Calquence for chronic lymphocytic leukaemia
8 December 2020 - NICE has published preliminary guidelines backing use of AstraZeneca's Calquence (acalabrutinib) as an NHS funded treatment ...
Posted by Michael Wonder on 08 Dec 2020
Britain begins vaccine rollout, first person vaccinated
8 December 2020 - A 90-year-old British grandmother has become the first person in the world to receive the Pfizer ...
Posted by Michael Wonder on 02 Dec 2020
Britain becomes the first country to license a fully tested COVID-19 vaccine
1 December 2020 - Inoculations with the Pfizer-BioNTech jab could start in less than a week. ...
Posted by Michael Wonder on 01 Dec 2020
Innovative technology to detect abnormal heart rhythms recommended by NICE for NHS use while further data is collected
1 December 2020 - Zio ZT is the first assessment, via the NICE digital health technologies guidance development pilot project, to ...
Posted by Michael Wonder on 30 Nov 2020
UK secures another two million doses of Moderna’s COVID-19 vaccine
30 November 2020 - The UK government has secured an additional two million doses of Moderna’s COVID-19 vaccine mRNA-1273, taking ...
Posted by Michael Wonder on 29 Nov 2020
Will COVID-19 vaccines be cost effective—and does it matter?
26 November 2020 - The costs of other pandemic measures mean that covid-19 vaccines will probably turn out to be ...
Posted by Michael Wonder on 25 Nov 2020
Merck racks up another NICE recommendation for Keytruda
25 November 2020 - That makes it number 12. ...
Posted by Michael Wonder on 25 Nov 2020
NICE publishes final guidance on Nubeqa
25 November 2020 - NICE has completed its assessment of darolutamide for use in combination with androgen deprivation therapy for ...
Posted by Michael Wonder on 24 Nov 2020
NICE backs Braftovi for BRAF positive colorectal cancer
24 November 2020 - NICE has back Pierre Fabre’s Braftovi plus cetuximab for the treatment of BRAF positive metastatic colorectal ...
Posted by Michael Wonder on 24 Nov 2020
New option for people with difficult-to-treat multiple myeloma is recommended for use in Cancer Drugs Fund by NICE
24 November 2020 - Around 5,700 cases of multiple myeloma are diagnosed each year in the UK. ...
Posted by Michael Wonder on 19 Nov 2020
NICE recommends another medicine for patients with multiple myeloma
18 November 2020 - Recommended for listing in the Cancer Drugs Fund. ...
Posted by Michael Wonder on 19 Nov 2020
NICE is getting ready for the end of the transition period after Brexit
19 November 2020 - NICE has a key role in evaluation and access to new and innovative products for the health ...
Posted by Michael Wonder on 18 Nov 2020
NICE backs Lilly’s Emgality for migraine, adding pressure on Novartis
18 November 2020 - UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the ...
Posted by Michael Wonder on 17 Nov 2020
UK strikes deal for five million doses of Moderna’s COVID-19 vaccine
17 November 2020 - The UK government has secured access to five million doses of Moderna’s COVID-19 vaccine after interim ...